Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Late-breaking cardiovascular drug trials took center stage at ACC.25
Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.
Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.

healthcare value value-based care money dollar

Cardiology Funding Roundup: Cardurion, Kestra, TRiCares all secure key investments

Businesses in the cardiovascular health space have been busy in recent weeks, announcing one big financing round after another.

Pharmacists help lower stroke risk in patients with undiagnosed, undertreated AFib

Researchers described pharmacies as an “attractive setting for community-based AFib screening."

PHOTO GALLERY: AMA display of medical quackery and ineffective, dangerous alternative medicine

The American Medical Association has a collection of artifacts on health fraud quackery at its Chicago headquarters office.

weight loss scale overweight obese lose weight pounds

Diabetes drug tirzepatide linked to more significant weight loss than semaglutide

Both tirzepatide (Mounjaro) and semaglutide (Ozempic) have made headlines in recent months for their benefits in broad patient populations. This new analysis compared the two medications in obese/overweight adults with and without type 2 diabetes.

Blood pressure drug could make leukemia more responsive to chemotherapy

“This finding shows great potential to enhance the success of chemotherapy while protecting the heart," one researcher said.

Biden Administration lowers prices for 64 prescription drugs, including 3 prescribed by cardiologists

The new list of discounted drugs includes an anticoagulant, a beta-blocker used to treat atrial fibrillation and much more.

A historic moment in diabetes care: Teva launches first-ever generic GLP-1 in US

Teva Pharmaceuticals has officially launched generic liraglutide injections in the United States. Novo Nordisk currently sells liraglutide under the brand name Victoza.

tirzepatide injections Zepbound Eli Lilly

Diabetes drug resolves sleep apnea in up to 52% of patients—is FDA approval in the cards?

Based on positive results from two different trials, Eli Lilly and Company hopes to secure a new FDA approval for tirzepatide in the months ahead.

Pharmaceutics

Late-breaking cardiovascular drug trials took center stage at ACC.25

Quality of care for heart patients does not improve in first year of ACO participation

Key takeaways from ACC.25: Advances in cardiovascular science

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’